These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35970303)

  • 1. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy.
    Lee D; Jordan AI; Menges MA; Lazaryan A; Nishihori T; Gaballa SR; Shah BD; Pinilla-Ibarz J; Baluch A; Klinkova OV; Chavez JC; Jain MD; Locke FL
    Transplant Cell Ther; 2023 Apr; 29(4):277.e1-277.e9. PubMed ID: 35970303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation.
    Tembo G; Mayuni M; Kamng'ona R; Chimgoneko L; Chiwala G; Sichone S; Galafa B; Thole F; Mkandawire C; Chirwa AE; Nsomba E; Nkhoma V; Ngoliwa C; Toto N; Makhaza L; Muyaya A; Kudowa E; Henrion MYR; Dula D; Morton B; Chikaonda T; Gordon SB; Jambo KC
    Vaccine; 2024 Apr; 42(12):2975-2982. PubMed ID: 38570270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence of immunity in children aged 2 months and 7 months - 5 years old after primary immunization with 13-valent pneumococcal conjugate vaccine.
    Li G; Ren T; Zhang H; Ti J; Chang X; Yin S; Guan Y; Liu G; Liang Q; Liu J
    Vaccine; 2024 Oct; 42(24):126209. PubMed ID: 39217777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients.
    Oesterreich S; Lindemann M; Goldblatt D; Horn PA; Wilde B; Witzke O
    Vaccine; 2020 Apr; 38(17):3339-3350. PubMed ID: 32178906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 13-Valent Pneumococcal Conjugate Vaccine Elicits Serological Response and Lasting Protection in Selected Patients With Primary Humoral Immunodeficiency.
    Robbins A; Bahuaud M; Hentzien M; Maestraggi Q; Barbe C; Giusti D; Le Naour R; Batteux F; Servettaz A
    Front Immunol; 2021; 12():697128. PubMed ID: 34290713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.
    Millar EV; O'Brien KL; Bronsdon MA; Madore D; Hackell JG; Reid R; Santosham M
    Clin Infect Dis; 2007 May; 44(9):1173-9. PubMed ID: 17407035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy.
    Bansal R; Vergidis P; Tosh PK; Wilson J; Hathcock M; Khurana A; Bennani NN; Paludo J; Villasboas JC; Wang Y; Ansell SM; Johnston PB; Freeman C; Lin Y
    Transplant Cell Ther; 2024 Apr; 30(4):455.e1-455.e7. PubMed ID: 38346643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
    Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
    Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
    Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
    Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
    Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
    Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients.
    Hung TY; Kotecha RS; Blyth CC; Steed SK; Thornton RB; Ryan AL; Cole CH; Richmond PC
    Cancer; 2017 Nov; 123(21):4215-4223. PubMed ID: 28696530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection.
    Romaru J; Bahuaud M; Lejeune G; Hentzien M; Berger JL; Robbins A; Lebrun D; N'Guyen Y; Bani-Sadr F; Batteux F; Servettaz A
    Front Immunol; 2021; 12():791147. PubMed ID: 34987514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.
    Pasiarski M; Rolinski J; Grywalska E; Stelmach-Goldys A; Korona-Glowniak I; Gozdz S; Hus I; Malm A
    PLoS One; 2014; 9(12):e114966. PubMed ID: 25506837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of pneumococcal antibodies after primary immunisation with a polysaccharide-protein conjugate vaccine.
    Zimmermann P; Perrett KP; Berbers G; Curtis N
    Arch Dis Child; 2019 Jul; 104(7):680-684. PubMed ID: 30796020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia.
    Takeshita K; Takeuchi N; Takahashi Y; Fukasawa C; Hishiki H; Hoshino T; Ishiwada N; Shimojo N
    Hum Vaccin Immunother; 2021 Oct; 17(10):3687-3691. PubMed ID: 34213395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
    Lupinacci R; Rupp R; Wittawatmongkol O; Jones J; Quinones J; Ulukol B; Dagan R; Richmond P; Stek JE; Romero L; Koseoglu S; Tamms G; McFetridge R; Li J; Cheon K; Musey L; Banniettis N; Bickham K;
    Vaccine; 2023 Jan; 41(5):1142-1152. PubMed ID: 36621410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.